Novartis’ Blockbuster Hopeful Leqvio Faces Perils Of Medicare’s Pricing Policy On Small Molecules
Executive Summary
Medicare’s pending price negotiation program could impact the longevity of the Part B cholesterol drug Leqvio. Novartis CEO Vas Narasimhan notes the upcoming redesign of the Part D benefit could boost pricing pressure on Kisqali.
You may also be interested in...
Novartis’ Entresto, Medicare Price Negotiation And The Impact Of ‘Bona Fide’ Competition
Entresto may be subject to a negotiated price in Medicare Part D for one year before it will be excused because of generic competition under the government's current approach to implementing the program, Novartis predicted. The program could also envelop Kisqali in a few years, but the firm is not making adjustments on Leqvio and pelacarsen in response to the IRA.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
Republican Leaders In Congress Want To Undercut Drug Pricing Law: What’s The Opportunity?
As Republicans expand their power in Congress, experts weigh in on prospects for significant changes to the Medicare price negotiation law and what the GOP might do to hamper implementation of the program.